What is a goodwill impairment charge?

A goodwill impairment charge is a non-cash accounting charge that a company records when the fair value of its goodwill is less than its carrying value on the balance sheet. Goodwill typically arises from acquisitions where the purchase price exceeds the fair value of the acquired company's identifiable net assets. An impairment means that the acquired business is not performing as well as expected, reducing its value.

How will this impairment charge affect Boston Scientific's stock price?

Goodwill impairment charges are non-cash expenses, meaning they do not involve an outflow of cash. While they will reduce reported net income and earnings per share, they do not directly impact the company's cash flow or liquidity. Investor reaction can vary; some investors may focus on the underlying operational reasons for the impairment, while others may be concerned about the magnitude of the charge and its implications for future growth and profitability in the EMEA region.

What is the significance of the impairment related to Sadra Medical Inc.?

The $110 million impairment charge for purchased R&D intangible assets from the Sadra Medical Inc. acquisition indicates that the company's revised expectations for completing and commercializing in-process projects are lower than initially anticipated. This suggests challenges or increased costs associated with bringing these specific products to market.

Are there any other financial impacts beyond the impairment charges?

This 8-K filing specifically addresses material impairments. While these charges significantly impact the reported financial results for the quarter, the filing does not detail other potential financial impacts or operational changes. Investors should refer to subsequent financial reports (like the 10-Q) for a comprehensive view of the company's financial performance and position.

BSX 8-K: Financial Events

Summary

Boston Scientific Corporation (BSX) announced a significant non-cash goodwill impairment charge of approximately $3.405 billion for its Europe, Middle East, and Africa (EMEA) reporting unit for the quarter ended June 30, 2012. This impairment is primarily attributed to lower projected long-term growth rates in the European market, influenced by macroeconomic factors and the company's performance. In addition to the goodwill impairment, the company also recorded an $110 million impairment charge for purchased research and development intangible assets related to the Sadra Medical Inc. acquisition. This is due to revised expectations regarding the effort, time, and cost to commercialize the related in-process projects. While the goodwill impairment charge is subject to finalization within a range of $3.1 billion to $3.7 billion, these charges will impact the company's financial statements for the affected period.

Key Highlights

1Boston Scientific recorded an estimated $3.405 billion non-cash goodwill impairment charge for its EMEA reporting unit.
2The impairment is driven by lower projected long-term growth rates in the European market due to macroeconomic factors and company performance.
3An additional $110 million impairment charge was recorded for purchased R&D intangible assets related to the Sadra Medical Inc. acquisition.
4The goodwill impairment charge is an estimate and subject to finalization, expected to be between $3.1 billion and $3.7 billion.
5These are non-cash charges and do not affect current cash flow, but will impact reported earnings.
6The company is providing a cautionary statement regarding forward-looking information and potential risks that could affect future results.

BOSTON SCIENTIFIC CORP 8-K Report, Material Impairment (Jul 26, 2012)

Summary

Key Highlights

Frequently Asked Questions